According to Dr. Patrick Lu, CEO of Sirnaomics, Dr. Lebel's promotion will enrich Sirnaomics' ability to advance its clinical-stage and pre-clinical RNAi-based treatments. Dr. Lebel himself expressed commitment to lead Sirnaomics' RNAi pipeline through clinical development to the commercial stage.

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase II clinical outcomes in oncology for an RNAi therapeutic for its cor...